ARTICLE | Company News
Merck Serono licenses Intrexon's CAR T tech
March 31, 2015 1:06 AM UTC
The Merck Serono division of Merck KGaA (Xetra:MRK) licensed technology from Intrexon Corp. (NYSE:XON) to develop chimeric antigen receptor (CAR) T cell therapies against two undisclosed cancer targets.
Merck Serono will pay Intrexon $115 million up front and will provide research funding for the two targets it selects. Intrexon is eligible for $826 million in milestones, plus tiered royalties. Intrexon will share the deal's proceeds equally with existing CAR T partner Ziopharm Oncology Inc. (NASDAQ:ZIOP). ...